MedPacto, Inc. (235980.KQ)
KRW 4585.0
(-1.4%)
KRW 4585.0
(-1.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.56 Billion KRW | -87.31% |
| 2022 | 75.36 Billion KRW | -16.08% |
| 2021 | 89.8 Billion KRW | 3161.75% |
| 2020 | 2.75 Billion KRW | 37.33% |
| 2019 | 2 Billion KRW | -92.64% |
| 2018 | 27.23 Billion KRW | 134.27% |
| 2017 | 11.62 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.41 Billion KRW | -4.25% |
| 2024 Q1 | 9.83 Billion KRW | 2.82% |
| 2023 Q3 | 11.93 Billion KRW | 10.38% |
| 2023 FY | 9.56 Billion KRW | -87.31% |
| 2023 Q4 | 9.56 Billion KRW | -19.86% |
| 2023 Q2 | 10.81 Billion KRW | -6.57% |
| 2023 Q1 | 11.57 Billion KRW | -84.64% |
| 2022 Q4 | 75.36 Billion KRW | 2.45% |
| 2022 Q2 | 69.49 Billion KRW | 3.82% |
| 2022 FY | 75.36 Billion KRW | -16.08% |
| 2022 Q1 | 66.94 Billion KRW | -25.45% |
| 2022 Q3 | 73.56 Billion KRW | 5.85% |
| 2021 Q4 | 89.8 Billion KRW | 0.34% |
| 2021 Q1 | 98.81 Billion KRW | 3910.88% |
| 2021 Q2 | 91.8 Billion KRW | -7.09% |
| 2021 FY | 89.8 Billion KRW | 3161.75% |
| 2021 Q3 | 89.5 Billion KRW | -2.51% |
| 2020 Q4 | 2.46 Billion KRW | 0.0% |
| 2020 FY | 2.75 Billion KRW | 37.33% |
| 2019 FY | 2 Billion KRW | -92.64% |
| 2018 FY | 27.23 Billion KRW | 134.27% |
| 2017 FY | 11.62 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 94.356% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -408.717% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 87.361% |
| Bioneer Corporation | 80.61 Billion KRW | 88.133% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | 52.14% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 92.953% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 90.221% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 86.996% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 99.105% |
| Medy-Tox Inc. | 137.14 Billion KRW | 93.025% |
| Peptron, Inc. | 16.36 Billion KRW | 41.562% |
| Amicogen, Inc. | 248.12 Billion KRW | 96.145% |
| Genexine, Inc. | 79.68 Billion KRW | 87.995% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | 67.326% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | 76.828% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 91.164% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | 86.912% |
| SillaJen, Inc. | 19.4 Billion KRW | 50.695% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 94.659% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 81.776% |
| Genomictree Inc. | 7.81 Billion KRW | -22.445% |
| D&D Pharmatech | 23.98 Billion KRW | 60.119% |
| EASY BIO,Inc. | 105.86 Billion KRW | 90.965% |
| GI Innovation, Inc. | 9.63 Billion KRW | 0.731% |